Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
  • Publication number: 20100080756
    Abstract: CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases.
    Type: Application
    Filed: September 23, 2009
    Publication date: April 1, 2010
    Inventors: Wei Han, Huili Lu, Di Xiang
  • Patent number: 7687496
    Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: March 30, 2010
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
  • Patent number: 7687497
    Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: March 30, 2010
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
  • Publication number: 20100074927
    Abstract: Microparticle carriers, particularly protein-encapsulated microbubbles, are used to deliver antiproliferative drugs to target sites in a subject. In particular, antirestenotic drugs are delivered to areas of vascular injury for treatment or prevention of hyperproliferative disease, e.g. stenosis, in blood vessels; and antineoplastic drugs are targeted to tumor sites.
    Type: Application
    Filed: September 17, 2009
    Publication date: March 25, 2010
    Inventors: Patrick L. Iversen, Nicholas Kipshidze
  • Publication number: 20100076009
    Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
    Type: Application
    Filed: September 2, 2009
    Publication date: March 25, 2010
    Inventors: Rheal A. Towner, Robert A. Floyd
  • Publication number: 20100076008
    Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.
    Type: Application
    Filed: February 9, 2009
    Publication date: March 25, 2010
    Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
  • Publication number: 20100068265
    Abstract: A pharmaceutical composition in the form of a gelatin capsule comprising a pharmaceutically acceptable acid.
    Type: Application
    Filed: December 18, 2007
    Publication date: March 18, 2010
    Inventors: Isabel Ottinger, Agnes Taillardat
  • Publication number: 20100069291
    Abstract: A first aspect of the invention relates to a combination comprising 2?-cyano-2?-deoxy-N4-palmitoyl-1-?-D-arabinofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from: (a) a HDAC inhibitor; and (b) a topoisomerase inhibitor selected from etoposide, topotecan and SN-38, or a prodrug thereof. A second aspect relates to a pharmaceutical product comprising (i) 2?-cyano-2?-deoxy-N4-palmitoyl-1-?-D-arabinofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and (ii) a cytotoxic agent selected from: (a) a HDAC inhibitor; and (b) a topoisomerase inhibitor selected from etoposide, topotecan and SN-38, or a prodrug thereof, as a combined preparation for simultaneous, sequential or separate use in therapy.
    Type: Application
    Filed: December 19, 2007
    Publication date: March 18, 2010
    Applicant: CYCLACEL LIMITED
    Inventors: Simon Green, Ian Fleming
  • Publication number: 20100068303
    Abstract: This invention relates to compositions and methods utilizing a chemotherapeutic drug and 6-bromoindirubin3?-oxime (BIO) for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that BIO works synergistically with chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells.
    Type: Application
    Filed: February 25, 2008
    Publication date: March 18, 2010
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventor: John S. Yu
  • Publication number: 20100062077
    Abstract: The use of a compound of formula (I), is disclosed in treating and/or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in a mixture with anticancer agents. An improved anticancer treatment with reduced CIPN-related side effects is also provided.
    Type: Application
    Filed: November 14, 2007
    Publication date: March 11, 2010
    Inventors: Carlo Farina, Carla Ghelardini, Paola Petrillo
  • Publication number: 20100063083
    Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.
    Type: Application
    Filed: October 12, 2009
    Publication date: March 11, 2010
    Applicant: Dr. Reddy's Laboratories LTD.
    Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
  • Publication number: 20100056555
    Abstract: New methods of treating Ras associated cancer, and especially for treating cancer that is resistant or refractory to other treatment methods, including resistant or refractory to treatment with C225 and/or CPT-11, are provided. The new methods employ PEG-conjugated 7-ethyl-10-hydroxycampothecin, alone, or in combination with other art-known anticancer agents or modalities.
    Type: Application
    Filed: August 28, 2009
    Publication date: March 4, 2010
    Applicant: ENZON PHARMACEUTICALS, INC.
    Inventors: Ivan HORAK, Puja SAPRA
  • Publication number: 20100055201
    Abstract: The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.
    Type: Application
    Filed: October 26, 2007
    Publication date: March 4, 2010
    Inventor: Michael A. Zeligs
  • Patent number: 7671067
    Abstract: The present invention relates to methods of treatment of non-Hodgkin's lymphomas. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxy-camptothecin to patients in need thereof.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: March 2, 2010
    Assignee: Enzon Pharmaceuticals, Inc.
    Inventor: Puja Sapra
  • Publication number: 20100048603
    Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.
    Type: Application
    Filed: February 7, 2008
    Publication date: February 25, 2010
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Claudio Pisano, Loredana Vesci, Franco Zunino
  • Publication number: 20100041619
    Abstract: The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative.
    Type: Application
    Filed: July 28, 2009
    Publication date: February 18, 2010
    Inventors: Yves Pommier, Yongwei Zhang, Arun K. Ghosh
  • Publication number: 20100034813
    Abstract: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
    Type: Application
    Filed: November 8, 2007
    Publication date: February 11, 2010
    Inventors: Yi Xia, Kris G. Mendenhall, Paul A. Barsanti, Annette O. Walter, David Duhl, Paul A. Renhowe
  • Publication number: 20100035911
    Abstract: A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of microtubule structure or function; or (b) a combination containing fenretinide (i.e., N-(4-hydrophenyl) retinamide, 4-HPR) and ABT-751 (i.e., N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide). Vitamin A derivatives that may be useful for this invention according to (a) include, but are not limited to, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide. Microtubule inhibitors that may be useful for this invention according to (a) include, but are not limited to, inhibitors of the Vinca binding domain (e.g., vincristine, vinblastine, vinorelbine, and cryptophycin 52), inhibitors of the Taxane domain (e.g.
    Type: Application
    Filed: May 16, 2007
    Publication date: February 11, 2010
    Inventors: Barry James Maurer, C. Patrick Reynolds
  • Publication number: 20100028338
    Abstract: A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation.
    Type: Application
    Filed: December 13, 2005
    Publication date: February 4, 2010
    Inventors: Sara Zaknoen, Margaret Ma Woo, Richard William Versace, Claudio Pisano, Loredana Vesci
  • Patent number: 7652027
    Abstract: A group of novel phenanthroindolizidine alkaloid compounds as shown and their use in treating cancer. Also disclosed are methods of using phenanthroindolizidine alkoid compounds in suppressing NO and TNF-? production, inhibiting MEKK1 activity and cyclooxygenase II expression, and treating NO-related disorders.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: January 26, 2010
    Assignee: National Health Research Institutes
    Inventors: Shiow-ju Lee, Cheng-Wei Yang
  • Publication number: 20100015046
    Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
    Type: Application
    Filed: August 11, 2009
    Publication date: January 21, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Serengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
  • Publication number: 20100009930
    Abstract: In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.
    Type: Application
    Filed: July 14, 2009
    Publication date: January 14, 2010
    Applicant: BiPar Sciences, Inc.
    Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
  • Publication number: 20100010032
    Abstract: Novel camptothecin derivatives having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them.
    Type: Application
    Filed: June 16, 2007
    Publication date: January 14, 2010
    Applicant: Indena S.p.A.
    Inventors: Gabriele Fontana, Ezio Bombardelli, Carla Manzotti, Arturo Battaglia, Cristian Samori
  • Publication number: 20100008998
    Abstract: The present invention relates to a nanoparticle composition comprising a camptothecin derivative, solid polyethyleneglycol and an anti-associative agent, and the process for preparing the same. Specifically, the present invention provides a composition comprising a nanoparticle of the camptothecin derivative, which is prepared by solid-dispersing the poorly water soluble camptothecin derivative in polyethyleneglycol and dissolving the solid dispersions in an aqueous solution containing an anti-associative agent. The composition of the present invention stabilizes the camptothecin derivative lactone form in body fluid for effective anticancer activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: January 14, 2010
    Applicant: SAMYANG CORPORATION
    Inventors: Hye Won Kang, Eun Young Yim, Min Hyo Seo
  • Publication number: 20100003246
    Abstract: New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: March 19, 2009
    Publication date: January 7, 2010
    Inventors: Zilin Hunag, Jeff Jin, Timothy Machajewski, William R. Antonios-McCrea, Maureen McKenna, Daniel Poon, Paul A. Renhowe, Martin Sendzik, Cynthia Shafer, Aaron Smith, Yongjin Xu, Qiong Zhang, Zheng Chen
  • Publication number: 20100004276
    Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
    Type: Application
    Filed: July 10, 2009
    Publication date: January 7, 2010
    Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna Santhapuram, Apparao Satyam, Joseph Anand Reddy
  • Publication number: 20100003324
    Abstract: The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.
    Type: Application
    Filed: June 30, 2009
    Publication date: January 7, 2010
    Applicant: OsteoGeneX Inc.
    Inventors: Debra Ellies, William Rosenberg
  • Publication number: 20090324620
    Abstract: The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof.
    Type: Application
    Filed: August 25, 2009
    Publication date: December 31, 2009
    Applicant: The Administrators of the Tulane Educational Fund
    Inventors: Joseph A. Fuselier, David H. Coy
  • Publication number: 20090325996
    Abstract: New camptothecin derivatives with the following structure of the formula (I), their use and the pharmaceutical compositions containing the same. The compounds of the present invention have good anti-tumor activities and good solubility in water, and can be used in development of medicines.
    Type: Application
    Filed: January 17, 2007
    Publication date: December 31, 2009
    Inventors: Wei Lu, Jian Ding, Heyong Gao, Liping Lin, Yi Chen
  • Publication number: 20090324741
    Abstract: An injectable polymer-lipid blend is provided. The blend may provide a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty acid or a fatty aldehyde, such as laurinaldehyde, having an acyl chain length of C8-C16. The rheological properties of the blend relates to the ratio of the components and to the acyl chain length of the fatty acid. The injectable system is well suited for the delayed release of pharmaceutically active agents in the treatment of cancer and other diseases requiring localized drug delivery.
    Type: Application
    Filed: August 28, 2008
    Publication date: December 31, 2009
    Inventors: Christine ALLEN, Justin GRANT, Jaepyoung CHO, Patrick LIM SOO, Micheline PIQUETTE-MILLER
  • Patent number: 7638528
    Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: December 29, 2009
    Assignees: Wake Forest University School of Medicine, The University of North Carolina at Chapel Hill
    Inventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
  • Publication number: 20090318487
    Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.
    Type: Application
    Filed: July 27, 2009
    Publication date: December 24, 2009
    Inventors: Anna Di Rienzo, Lalitha Iyer, Mark J. Ratain
  • Publication number: 20090311264
    Abstract: The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses.
    Type: Application
    Filed: April 7, 2009
    Publication date: December 17, 2009
    Applicant: AEterna Zentaris GmbH
    Inventors: Herbert Irschik, Rolf Jansen, Florenz Sasse, Silke Baasner, Peter Schmidt, Eckhard Gunther
  • Publication number: 20090306103
    Abstract: Pyridonecarboxamide derivatives, pharmaceutical compositions which contain the same and methods for treating hyper-proliferative disorders and angiogenesis disorders using the same.
    Type: Application
    Filed: May 18, 2007
    Publication date: December 10, 2009
    Inventors: Stephen Boyer, David Cantin, Sidney X. Liang
  • Publication number: 20090298743
    Abstract: Disclosed are compositions comprising a hydrophobic active agent, a polymer and a reconstitution enhancing agent. Reconstitution of the lyophilized form of the compositions takes less time than in the absence of the enhancing agent.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 3, 2009
    Applicant: NOVARTIS AG
    Inventors: Marc Besman, John Carpenter, Mark Manning, Lotte McNamara, Rajiv Nayar
  • Publication number: 20090298785
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Application
    Filed: July 24, 2007
    Publication date: December 3, 2009
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Publication number: 20090297506
    Abstract: The invention discloses a method for classification of cancer in an individual having contracted cancer. The method of classification involves the determination of microsatellite status and a prognostic marker by examining gene expression patterns. The invention also relates to various methods of treatment of cancer. Additionally, the present invention concerns a pharmaceutical composition for treatment of cancer and uses of the present invention. The invention also relates to an assay for classification of cancer.
    Type: Application
    Filed: December 23, 2004
    Publication date: December 3, 2009
    Applicant: Aros Applied Biotechnology ApS
    Inventors: Torben Falck Orntoft, Paivi Laiho, Lauri A. Aaltonen, Mogens Kruhoffer, Jens Ledet Jensen
  • Publication number: 20090291049
    Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.
    Type: Application
    Filed: May 22, 2008
    Publication date: November 26, 2009
    Applicants: Universidade De Coimbra, Centro De Neurociencias E Biologia Celular
    Inventors: Joao Nuno Sereno de Almeida Moreira, Vera Lucia Dantas Nunes Caldeira de Moura, Sergio Paulo de Magalhaes Simoes, Maria da Conceicao Monteiro Pedroso de Lima
  • Publication number: 20090285878
    Abstract: The present invention is directed to liposomal compositions comprising a camptothecin, which are optimized to reduce camptothecin degradation and/or precipitation of camptothecin degradation products in the external medium. The invention further provides improved methods of formulating liposomal camptothecins, kits comprising liposome-encapsulated camptothecins, and methods of using the same to treat a variety of diseases and disorders, including cancer.
    Type: Application
    Filed: November 4, 2005
    Publication date: November 19, 2009
    Applicant: Tekmira Pharmaceuticals Corporation
    Inventors: Michael J. Hope, Barbara Mui, Thomas D. Madden
  • Publication number: 20090274762
    Abstract: A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum.
    Type: Application
    Filed: June 22, 2007
    Publication date: November 5, 2009
    Applicant: BIOCOMPATIBLES UK LIMITED
    Inventors: Sean Willis, Rosemary Palmer
  • Publication number: 20090275603
    Abstract: A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.
    Type: Application
    Filed: April 3, 2009
    Publication date: November 5, 2009
    Inventors: Jetze J. Tepe, Peddibhotla Satyamaheshwar
  • Publication number: 20090274698
    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, or ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 3, 2008
    Publication date: November 5, 2009
    Inventors: Shripad Bhagwat, Sharon Barr, Elizabeth A. Buck, Alexandra Eyzaguirre, Suzanne Russo
  • Patent number: 7612081
    Abstract: Compounds are disclosed with the general formula in which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as medicaments for the treatment of tumors and viral and parasite infections.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: November 3, 2009
    Assignees: Istituto Nazionale per lo Studio e la Cura dei Tumori, Sigma Tau Industrie Farvaceutiche Riunite S.p.A.
    Inventors: Giuseppe Giannini, Claudio Pisano, Loredana Vesci, Maria Ornella Tinti, Lucio Merlini, Sergio Penco, Franco Zunino
  • Publication number: 20090269281
    Abstract: The present invention includes compositions and methods for treating a patient with cardiac hypertrophy by providing the patient with an effective amount of a Calmodulin kinase kinase inhibitor that is sufficient to treat cardiac hypertrophy.
    Type: Application
    Filed: September 9, 2008
    Publication date: October 29, 2009
    Applicant: University of North Texas Health Science Center at Fort Worth
    Inventors: Stephen R. Grant, Thomas G. Valencia
  • Publication number: 20090263397
    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I) (e.g. OSI-906). Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, and ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I), in a pharmaceutically acceptable carrier. The present invention also provides a method of identifying tumor cells that will respond most favorably to treatment with a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor.
    Type: Application
    Filed: July 7, 2008
    Publication date: October 22, 2009
    Inventors: Elizabeth A. Buck, Alexandra Eyzaguirre, David M. Epstein, Mark R. Miglarese
  • Publication number: 20090258071
    Abstract: The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock copolymers, which permit the release of the pharmaceutically active agent when exposed to an environment having a particular pH. The compositions are particularly useful for the oral delivery of water insoluble pharmaceutically active agents.
    Type: Application
    Filed: March 20, 2009
    Publication date: October 15, 2009
    Applicant: Labopharm, Inc.
    Inventors: David Lessard, Laibin Luo, Dorothee Le Garrec, Damon Smith
  • Patent number: 7601733
    Abstract: A 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: October 13, 2009
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
  • Patent number: 7601732
    Abstract: A crystalline form of 5(S)-(2?-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2?-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2? that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: October 13, 2009
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Venkateswarlu Akella, Shanavas Alikunju, Ajaya Kumar Reka, Ramesh Mullangi, Raju Sirisilla, Subrahmanyam Duvvuri, Sriram Rajagopal
  • Patent number: 7598279
    Abstract: Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: October 6, 2009
    Assignee: SK Holdings Co., Ltd.
    Inventors: Yong Moon Choi, Choon-Gil Kim, Han-Ju Yi, Young-Sun Kang, Hyun-Seok Lee
  • Publication number: 20090247475
    Abstract: The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient.
    Type: Application
    Filed: May 12, 2006
    Publication date: October 1, 2009
    Applicants: The Regents of the University of California, The University of Chicago
    Inventors: Mark J. Ratain, Federico Innocenti, Deanna L. Kroetz, Samir Undevia, Tan D. Nguyen, Wanqing Liu